|
Aug. 06, 2008 |
|
|
Dec. 17, 2018 |
|
|
jRCT2080220584 |
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer |
|
GlaxoSmithKline K.K. |
||
https://glaxosmithkline.co.jp/legal/inquire3_1.html |
||
Interventional |
||
Refer to 'GSK Clinical Study Register' |
||
3 |
||
Refer to 'GSK Clinical Study Register' |
||
Refer to 'GSK Clinical Study Register' |
||
| 18age old over | ||
| No limit | ||
Both |
||
Non-Small Cell Lung Cancer |
||
investigational material(s) |
||
Refer to 'GSK Clinical Study Register' |
||
Refer to 'GSK Clinical Study Register' |
||
| GlaxoSmithKline K.K. | |
| JapicCTI-080606 | |